Working… Menu

Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03773172
Recruitment Status : Terminated (Early termination due to COVID-19)
First Posted : December 12, 2018
Last Update Posted : December 11, 2020
MedImmune LLC
Information provided by (Responsible Party):
Columbia University

Brief Summary:
This is a Phase 2, single-center, placebo controlled, double-blind, randomized crossover study to determine the effects of MEDI6012 on the metabolism of apolipoprotein B100 (apoB100) lipoproteins in individuals with stable atherosclerotic cardiovascular disease (ASCVD).

Condition or disease Intervention/treatment Phase
Cardiovascular Diseases Drug: MEDI6012 Drug: Placebo Phase 2

Detailed Description:
Atherosclerosis, characterized by excess fat deposit in arteries, is a progressive and life-threatening condition. Therefore, treatments that can remove fat deposits from the arteries are being developed. These treatments may prevent subsequent heart attacks or other cardiovascular events, addressing an unmet medical need. MEDI16012 is a new drug that targets a substance produced by the body to assist participants in breaking down the bodies "good" fat. The investigators are interested in understanding why MEDI6012 increases the good fat, but also why it increases other types of "bad" fat such as low-density lipoprotein-C (LDL-C).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study to Evaluate the Effects of Two Doses Over 48 Hours of MEDI6012 on Apolipoprotein B100 Metabolism in Subjects With Stable Atherosclerotic Cardiovascular Disease
Actual Study Start Date : January 31, 2019
Actual Primary Completion Date : May 20, 2020
Actual Study Completion Date : May 20, 2020

Arm Intervention/treatment
Placebo Comparator: Placebo Control Group
Subjects will receive placebo treatment to mimic active treatment.
Drug: Placebo
The placebo will mimic the active treatment.
Other Name: Placebo compound provided by funding agency

Active Comparator: Active treatment
IV push loading dose of 300 mg MEDI6012 followed by a 150 mg maintenance dose of MEDI6012 at 48 hours.
Drug: MEDI6012
MEDI6012 is recombinant human lecithin-cholesterol acyltransferase (rhLCAT), an approximately 60 kilodalton, glycosylated, single-chain protein consisting of 416 amino acids produced via Chinese hamster ovary cell culture. It is being explored as an acute treatment to reduce the risk of recurrent cardiovascular events as an adjunct to the standard of care in patients with acute myocardial infarction (MI). MEDI6012 and ACP501 have the identical amino acid sequence and are therefore considered the same molecular entity.
Other Name: Stable Isotopes

Primary Outcome Measures :
  1. Percent Change in FCR of LDL-apoB100 (pools/day) [ Time Frame: Up to 48 hours from first dose ]
    Fractional Clearance Rate (FCR) of lipoprotein B.

Secondary Outcome Measures :
  1. PR of LDL apoB100 (mg/kg/day) [ Time Frame: Up to 48 hours from first dose ]
    Production Rate (PR) of LDL apoB 100.

Other Outcome Measures:
  1. ADA Measurement [ Time Frame: Up to 60 days post administration of first dose ]
    To access the immunogenicity of MEDI6012, anti-drug antibodies (ADA) will be measured.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Adult male and female subjects (non-childbearing potential for females) ages 35 through 80 years at the time of screening who are capable of providing informed consent prior to screening and any protocol-related procedures.
  2. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act (HIPAA) in the USA) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
  3. Ability to complete and meet all eligibility requirements for randomization within 28 days of informed consent (56 days if washing out from lipid altering agent other than statins or ezetimibe).
  4. A diagnosis of stable atherosclerotic cardiovascular disease (CVD) documented prior to screening:

    • Coronary artery disease defined as a history of prior myocardial infarction, coronary revascularization, history of coronary atherosclerosis based on invasive or non-invasive imaging, and/or abnormal stress testing diagnostic of coronary artery disease.
    • Carotid artery disease (extracranial internal carotid artery (ICA) stenosis) defined as evidence of carotid atherosclerosis by carotid imaging, or history of percutaneous or surgical carotid revascularization
    • Peripheral artery disease defined as ankle-brachial index < 0.90 and claudication, or prior peripheral revascularization for ischemia, or evidence of lower extremity (below the inguinal ligament) atherosclerosis on invasive or noninvasive imaging
  5. Currently receiving statin as standard of care, at a stable dose for ≥ 8 weeks prior to screening and intended to remain at a stable dose throughout the study duration. Subjects may also be receiving ezetimibe, 10 mg/day for ≥ 8 weeks prior to screening.
  6. Nonsterilized males who are sexually active with a female partner of childbearing potential must use condom and spermicide from Day 1 through the end of their participation in the study. Because male condom and spermicide is not a highly effective contraception method it is strongly recommended that female partners of a male study subjects also use a highly effective method of contraception throughout this period.

Exclusion Criteria:

  1. Unstable cardiovascular conditions within 3 months prior to screening, including acute coronary syndrome (ACS), stroke or transient ischemia attack, critical limb ischemia, non-elective arterial revascularization, life-threatening arrhythmias, or heart failure hospitalization.
  2. Elective arterial revascularization (in any vascular territory) in the past 1 month. Any planned arterial revascularization (coronary, peripheral or carotid).
  3. New York Heart Association (NYHA) Class III or IV congestive heart failure or treatment with advanced therapies (cardiac transplant, ventricular assist device, cardiac resynchronization therapy,and/or chronic IV inotropic support), or severe valvular heart disease.
  4. Body mass index < 18 or > 45.
  5. Lipid measurements with any of the following:

    1. Triglycerides (TG) > 400 mg/dL
    2. LDL-C > 120 mg/dL
    3. High-density lipoprotein C (HDL-C) > 70 mg/dL for males or > 80 mg/dL for females.
  6. Clinically significant vital sign abnormalities at screening or on Day -1:

    1. Systolic blood pressure (BP) < 90 or >160 mm Hg
    2. Diastolic BP > 100 mm Hg
  7. Females currently breastfeeding or of childbearing potential. Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or those who are not postmenopausal; defined as 12 months with no menses without an alternative medical cause and a follicle-stimulating hormone level in the central laboratory's normal range for post-menopausal phase is required at screening.
  8. Use of lipid-lowering medications, with the exception of statins and ezetimibe, and the following dietary supplements: ≥ 2 grams/day of fish oil (≥ 2 grams/day docosahexaenoic acid (DHA) and EPA combined), ≥ 30 grams/day of flaxseed oil or ground flaxseed, red yeast extract, > 100 mg/day of niacin. At the investigator's discretion, subjects may undergo a 6-week washout period of any exclusionary lipid-lowering agents with the expectation that post-washout lipid levels will be rechecked and acceptable per above criteria.
  9. History of any of the following:

    • Documented familial hypercholesterolemia
    • Chronic kidney disease defined by estimated glomerular filtration rate < 30 mL/min/1.73 m2 by the modification of diet in renal disease equation, or end stage renal disease treated with kidney transplant or renal replacement therapy
    • History of clinically overt chronic liver disease or biochemical evidence of liver disease
    • Poorly controlled endocrine disorder including:

      • Type 1 Diabetes excluded
      • Type 2 Diabetes Mellitus with glycated hemoglobin (HbA1c) > 8.0% as assessed at screening or
    • Uncontrolled thyroid disorder defined as thyroid stimulating hormone (TSH)> upper limit of normal (ULN) and abnormal free T4; subjects with thyroid deficiency should have received a stable dose of thyroid hormone for > 6 weeks prior to screening and have a normal TSH.
    • Current or previous use of systemic corticosteroids within 28 days prior to screening. Topical, intra-articular, intranasal, inhaled, and ophthalmic steroid therapies are allowed
    • History of severe infection or ongoing febrile illness within 30 days of screening, or a medical history of a chronic viral illness including hepatitis B or C virus, or human immunodeficiency virus (HIV).
    • History of active malignancy within 5 years (subjects with non-melanotic skin cancer may be included)
    • Any other disease or condition or laboratory value that, in the opinion of the investigator or medical monitor, would place the subject at an unacceptable risk or interfere with the evaluation of the investigative product.
    • Known allergy/hypersensitivity to any component of the investigational product formulation, other biologics, IV infusion equipment, plastics, adhesive or silicone, history of infusion site reactions with IV administration of other medicines, or ongoing clinically important allergy/hypersensitivity as judged by the investigator.
  10. Subjects who are legally institutionalized
  11. Previous Exposure to rhLCAT
  12. Concurrent enrollment in another clinical study of any investigational drug therapy or use of any biologicals within 6 months prior to screening or within 5 half-lives of an investigational agent or biologic, whichever is longer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03773172

Layout table for location information
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
MedImmune LLC
Layout table for investigator information
Principal Investigator: Henry Ginsberg, MD Columbia University
Layout table for additonal information
Responsible Party: Columbia University Identifier: NCT03773172    
Other Study ID Numbers: AAAS0459
First Posted: December 12, 2018    Key Record Dates
Last Update Posted: December 11, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Columbia University:
Lipid and Lipoprotein Metabolism
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases